Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 1214784
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BAY 1214784 is an orally available, potent, and selective small molecule antagonist of the human gonadotropin-releasing hormone receptor (hGnRH-R). It was developed to lower plasma luteinizing hormone (LH) levels as a mechanism to manage hormone-driven symptoms of uterine fibroids. In first-in-human studies in postmenopausal women, once-daily treatment with BAY 1214784 effectively reduced plasma LH levels by up to 49% and demonstrated good tolerability with low pharmacokinetic variability. The drug was designed to address limitations of existing GnRH-R blockers that can induce menopausal symptoms and affect bone mineralization. The developer is Bayer.
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on BAY 1214784.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY 1214784.